| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Dividendenbekanntmachungen (30.03.2026) | 9.804 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 113 JPY 0,6124 EUR ACOM CO LTD JP3108600002 10 JPY 0,0542 EUR ADAMAS TRUST INC US6496048405 0,23 USD 0... ► Artikel lesen | |
| 11:15 | Dividendenbekanntmachungen (31.03.2026) | 771 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1744 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1816 EUR ADVANCED FLOWER CAPITAL... ► Artikel lesen | |
| Mo | Anavex Life Sciences Corp.: Anavex Life Sciences Provides Comprehensive Regulatory Update | 529 | GlobeNewswire (Europe) | Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease Additional data submitted to the U.S. FDA with the objective... ► Artikel lesen | |
| 05:10 | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | 522 | inv3st.de | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| Mo | PDS Biotechnology Corporation: PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement | 514 | GlobeNewswire (Europe) | Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON,... ► Artikel lesen | |
| Mo | Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook | 383 | Business Wire | 2025 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the final results of the Phase... ► Artikel lesen | |
| Mo | Reploid: Anleihe wird stark nachgefragt | 349 | 4investors | Reploid hat eine Anleihe begeben. Dies geschieht im Rahmen einer Crowdfinancing-Kampagne. Die Anleihe hat ein Volumen von 1,5 Millionen Euro. Das Papier war klar überzeichnet. Verzinst wird das Papier... ► Artikel lesen | |
| 07:03 | MindMaze Therapeutics Holding SA: MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation | 330 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Study results
MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation... ► Artikel lesen | |
| 03:46 | CanSino Biologics Inc: CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader | 306 | JCN Newswire | HONG KONG, Mar 31, 2026 - (ACN Newswire) - HONG KONG, Mar 31, 2026 - (ACN Newswire) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry,... ► Artikel lesen | |
| Mo | Connect Biopharma Holdings Limited: Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD | 301 | GlobeNewswire (Europe) | - Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease - COPD) patients produced rapid improvement in FEV1 with many patients experiencing... ► Artikel lesen | |
| Mo | EQS-RPT: Marinomed Biotech AG: Veröffentlichung gemäß § 95a Abs. 5 AktienG mit dem Ziel der europaweiten Verbreitung | 273 | EQS Group (DE) | EQS Mitteilung über Geschäfte mit nahestehenden Personen: Marinomed Biotech AG
/ Veröffentlichung gemäß § 95a Abs. 5 AktienG
Marinomed Biotech AG: Veröffentlichung gemäß § 95a... ► Artikel lesen | |
| 07:34 | Galapagos NV: Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases | 248 | GlobeNewswire (Europe) | New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos
Following this transaction, the Company will continue to have a majority of its cash remaining... ► Artikel lesen | |
| Mo | Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results | 247 | ACCESS Newswire | ~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)... ► Artikel lesen | |
| Mo | Biogen Sayd FDA Grants Approval For High-Dose SPINRAZA Regimen For SMATreatment | 242 | AFX News | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday that the High Dose Regimen of SPINRAZA (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food... ► Artikel lesen | |
| 07:03 | BioVersys AG: BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health | 238 | EQS Group (EN) | BioVersys AG
/ Key word(s): Agreement
BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health 31.03.2026... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| SIGA TECHNOLOGIES | 5,265 | 0,52 | +9,88 % | 0,60 | 07.04.2026 | |
| BB BIOTECH | 47,300 | 2,47 | +5,22 % | 2,25 | 23.03.2026 | |
| CSL | 84,90 | 2,61 | +3,07 % | 1,84 | 10.03.2026 | |
| AMGEN | 307,40 | 8,39 | +2,73 % | 2,52 | 15.05.2026 | |
| RECORDATI | 48,320 | 1,30 | +2,69 % | 0,71 | 18.05.2026 | |
| NOVONESIS | 51,70 | 0,87 | +1,68 % | 4,25 | 20.03.2026 | |
| SINO BIOPHARM | 0,640 | 0,01 | +1,56 % | 0,05 | 24.06.2026 | |
| GENUS | 27,600 | 0,38 | +1,38 % | 0,11 | 05.03.2026 | |
| BIOMERIEUX | 91,35 | 0,90 | +0,99 % | 0,98 | 09.06.2026 | |
| BIO-TECHNE | 45,600 | 0,27 | +0,59 % | 0,08 | 13.02.2026 |